Last reviewed · How we verify

PLX-PAD — Competitive Intelligence Brief

PLX-PAD (PLX-PAD) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cell therapy. Area: Regenerative Medicine / Vascular Disease.

phase 3 Cell therapy Regenerative Medicine / Vascular Disease Biologic Live · refreshed every 30 min

Target snapshot

PLX-PAD (PLX-PAD) — Pluristem Ltd.. PLX-PAD is a placental-derived cell therapy that promotes tissue repair and regeneration through anti-inflammatory and pro-angiogenic mechanisms.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
PLX-PAD TARGET PLX-PAD Pluristem Ltd. phase 3 Cell therapy
Casgevy EXAGAMGLOGENE AUTOTEMCEL marketed Autologous genome-edited hematopoietic stem cell therapy BCL11A 2023-01-01
Stem Cell Stem Cell Neurogen Brain and Spine Institute marketed Cell therapy
Cord blood Cord blood New York Medical College marketed Hematopoietic stem cell therapy
Cord Blood Cell Cord Blood Cell China Spinal Cord Injury Network marketed Cell therapy
IL-2 pre-treated CD19 cells IL-2 pre-treated CD19 cells jiangjingting marketed Adoptive cell therapy CD19
hUCB hUCB StemCyte Taiwan Co., Ltd. marketed Allogeneic hematopoietic stem cell therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cell therapy class)

  1. Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León · 2 drugs in this class
  2. Bone Therapeutics S.A · 1 drug in this class
  3. DiscGenics, Inc. · 1 drug in this class
  4. Celavie Bioscences, LLC · 1 drug in this class
  5. China Spinal Cord Injury Network · 1 drug in this class
  6. City of Hope Medical Center · 1 drug in this class
  7. Brainstorm-Cell Therapeutics · 1 drug in this class
  8. Dr. Grant M. Pagdin · 1 drug in this class
  9. FDA Office of Orphan Products Development · 1 drug in this class
  10. Biosolution Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PLX-PAD — Competitive Intelligence Brief. https://druglandscape.com/ci/plx-pad. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: